Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dual EGFR Inhibition with Erlotinib and Panitumumab in mCRC
NCT00940316Phase 2Completed
- Sponsor
- Northwestern University
- Start
- Jan 2010
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of erlotinib in metastatic colorectal cancer (mCRC) (3 arms), sponsored by Northwestern University. Primary endpoint: Tumor Response Rate. Started Jan 2010; status: completed.
02
Drugs
erlotinib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00940316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00940316.